HomeInsightsResults

Aurobindo Pharma Ltd Quarterly Result

Aurobindo Pharma Ltd Quarterly Result

stocks purchased

₹ 0.0 Cr

Volume Transacted

(Nov 22, 2024)

stocks purchased

0.0 K

Stocks Traded

(Nov 22, 2024)

Last Updated on: Nov 22, 2024

Image

Aurobindo Pharma Ltd

NSE: AUROPHARMA

Net Profit

₹ 816.95

Last updated on: Nov 22, 2024

Key Highlights

  • The revenue of Aurobindo Pharma Ltd for the Sep '24 is ₹ 7932 crore as compare to the Jun '24 revenue of ₹ 7787 crore. This represent the growth of 1.8544022%.
  • The ebitda of Aurobindo Pharma Ltd for the Sep '24 is ₹ 1702 crore as compare to the Jun '24 ebitda of ₹ 1839 crore. This represent the decline of -7.431314%.
  • The net profit of Aurobindo Pharma Ltd for the Sep '24 is ₹ 816.95 crore as compare to the Jun '24 net profit of ₹ 918.22 crore. This represent the decline of -11.028943%.

Results Analysis

Market Price of Aurobindo Pharma Ltd

1M

1Y

3Y

5Y

Monitoring Aurobindo Pharma Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
21 Nov 20241220.2
19 Nov 20241247.9
18 Nov 20241235.15
14 Nov 20241248.3
13 Nov 20241249.4
12 Nov 20241267.4
11 Nov 20241287.85
08 Nov 20241327.55
07 Nov 20241350.5
06 Nov 20241394.65

Historical Revenue of Aurobindo Pharma Ltd

No data available

* All values are in crore

Historical EBITDA of Aurobindo Pharma Ltd

No data available

* All values are in crore

Historical Net Profit of Aurobindo Pharma Ltd

No data available

* All values are in crore

Aurobindo Pharma Ltd News Hub

News

Aurobindo Pharma Ltd drops for fifth straight session

Aurobindo Pharma Ltd fell for a fifth straight session today. The stock is quoting at Rs 1...

Read more

11 Nov 202413:14

News

Aurobindo Pharma to table results

Aurobindo Pharma will hold a meeting of the Board of Directors of the Company on 9 Novembe...

Read more

02 Nov 202412:52

News

Aurobindo Pharma completes acquisition of balance 49% stake in GLS Pharma

Aurobindo Pharma has completed the acquisition of balance 49% stake in its subsidiary, GLS...

Read more

25 Oct 202419:30

News

Aurobindo Pharma Ltd spurts 1.19%, up for fifth straight session

Aurobindo Pharma Ltd gained for a fifth straight session today. The stock is quoting at Rs...

Read more

09 Oct 202413:00

News

Aurobindo Pharma's step down subsidiary to divest its entire stake in a South African JV

Aurogen South Africa, (Aurogen) a wholly owned step-down subsidiary of Aurobindo Pharma in...

Read more

05 Oct 202410:19

News

Aurobindo Pharma's step down subsidiary to divest its entire stake in JV 'Novagen'

Aurogen South Africa (Aurogen), a wholly owned step-down subsidiary of Aurobindo Pharma in...

Read more

05 Oct 202410:21

Document

Annual Reports

Annual Report 2024

dropdown
download

Credit Ratings

Credit Report 2024

dropdown
download

Concalls

June 2023

TranscriptPPT

June 2022

TranscriptPPT

Aug 2021

PPT

June 2021

TranscriptPPT

June 2020

TranscriptPPT

Jan 2020

PPT

FAQ's For Aurobindo Pharma Ltd Quarterly Result

What is the EPS of Aurobindo Pharma Ltd stock?

The Earnings Per Share (EPS) of Aurobindo Pharma Ltd is 62.24. An EPS is the amount of net income attributed to each share of a common stock.

How is Aurobindo Pharma Ltd EPS calculated?

The EPS of Aurobindo Pharma Ltd is calculated by dividing the net income by the number of outstanding shares. The formula is EPS = (Net Income - Dividends on Preferred Stock) / Average Outstanding Shares.

How often does Aurobindo Pharma Ltd report its EPS?

Aurobindo Pharma Ltd typically reports its EPS quarterly and annually, in conjunction with its financial statements and earnings reports.

What factors can influence Aurobindo Pharma Ltd EPS?

Factors that influence the EPS of Aurobindo Pharma Ltd include revenue changes, cost fluctuations, operational efficiency, tax rates, and one-time gains or losses.

Can Aurobindo Pharma Ltd EPS growth indicate future performance?

Yes, consistent growth in Aurobindo Pharma Ltd EPS can suggest strong financial health and effective management, potentially indicating positive future performance.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199*